2001 guidelines for treating opportunistic infections in HIV-exposed and infected children, developed by a working group from the CDC, NIH, and IDSA. The report focuses on treatment considerations unique to infants, children, and adolescents in the United States, addressing differences in diagnosis, drug pharmacokinetics, and disease natural history compared to adults. The author is Lynne Mofenson from the National Institute of Child Health.
Use Cases
- Analyzing treatment recommendations for common pediatric opportunistic infections based on the described clinical considerations.
- Studying differences in drug dosing and toxicities between adults and children as highlighted in the description.
- Researching the natural history of primary vs. reactivated infections in pediatric HIV patients as discussed in the report.
Strengths
- Developed by a multi-agency U.S. working group including the CDC, NIH, and IDSA.
- Focuses on unique pediatric considerations including congenital infections and immature immune systems.
- Addresses specific challenges like laboratory diagnosis difficulties and drug formulation differences for children.
Limitations
- Row count and specific data format are unknown, limiting suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- Last update date is unknown; freshness unverified.
Provenance
- Source
- National Institute of Child Health, author Lynne Mofenson.
- Collection Method
- Guidelines developed by a convened working group.
- Time Range
- Guidelines developed in 2001.
- Geography
- Focus on the United States.